Blood-based biomarker developments: APOE genotyping, microRNA diagnostics, and automation-ready assay workflows are previewed. Expect lab-to-clinic-focused poster coverage and potential diagnostic scalability insights.
Key Takeaways
- Three biomarker posters will be presented at the Alzheimer’s Association International Conference in July 2026
- Presentations come from a CLIA-certified, CAP-accredited laboratory demonstrating clinical-grade assay development
- Shareholders approved an all-stock merger on 9 June 2026 with closing expected before fiscal 2027